Epidermal growth factor antagonizes vasopressin in vivo and in vitro  by Phillips, Paddy A. et al.
Kidney International, Vol. 45 (1994), pp. 1028—1 036
Epidermal growth factor antagonizes vasopressin
in vivo and in vitro
PADDY A. PHILLIPS, SHARON L. GRANT, A. FI0NA DAVIDSON, JOHN RIsvANIs,
JAYNE STEPHENSON, and CHRISTINE B. Gow
Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg and School of Agriculture,
La Trobe University, Bundoora, Victoria, Australia
Epidermal growth factor antagonizes vasopressin in vivo and in vitro.
Since EGF causes diuresis through a renal action and may antagonize
the hydroosmotic effect of AVP in vitro we investigated the antagonistic
action of EGF with AVP in vivo and the mechanism of the antagonism in
Vitro. Conscious ewes received i.m. injections of a selective AVP V2-
receptor agonist (1-desamino, D-Arg8 vasopressin acetate, DDAVP) every
12 hours for days 5 to 16. All ewes received an i.v. isotonic saline
infusion (100 mI/day) for days ito 8 and days 13 to 16, and i.v. EGF in
100 ml saline/day at doses of 0 (N = 8) or 10 (N = 8) pg/hr for days 9
to 12. DDAVP reduced both urine volume and water intake, and
increased urine osmolality. In contrast, simultaneous infusion of EGF
reversed the DDAVP-induced responses, resulting in a transient nega-
tive fluid balance, kaliuresis and a transient natriuresis (all P < 0.05).
When EGF treatment ceased, the effects of DDAVP treatment alone
gradually became apparent. From the in vitro studies, the AVP-related
peptides displaced specific AVP VI- and V2-receptor antagonist radio-
ligands from rat renal inner medullary membranes, whereas EGF had
no effect. However, EGF antagonized AVP V2-stimulated cAMP
production in a dose-dependent way (IC50 = 2 x 107M). Therefore, the
diuretic effect of EGF is not via direct antagonism of the antidiuretic
AVP V2-receptor but seems mediated by inhibition of the antidiuretic
AVP V2-receptor second messenger system.
Although it is known that epidermal growth factor (EGF) is
mitogenic for renal tubule cells in vitro [1, 2] and in vivo [3], it
is increasingly recognized that EGF may also influence renal
function causing altered sodium transport and water permeabil-
ity in vitro [4—6] and in vivo [7—91. In isolated cortical collecting
tubules, EGF antagonized arginine vasopressin (AVP)-stimu-
lated water transport [4]. Recently, we reported that chronic
long-term intravenous (i.v.) infusion of EGF into conscious
sheep caused diuresis, natriuresis and polydipsia [7—9]. The
doses of EGF reported to alter fluid and electrolyte balance in
sheep include 0.5 mg/day [7], 5 or 10 pjg/kg live weight per day
[8] and 10 or 20 pjg/hr [9]. These effects seemed primarily
caused by a direct renal action of EGF in that i.v. EGF infusion
into animals with fixed water intake caused diuresis, natriuresis
and negative fluid balance with compensatory polydipsia and
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sodium retention upon cessation of EGF infusion and ad libitum
water access [10]. The mechanism of these effects was unclear.
In the kidney AVP produces antidiuresis by activating the
AVP V2 (antidiuretic)-receptor subtype and its second messen-
ger system, adenylyl cyclase and cAMP generation. The aim of
the in vivo experiment reported here was to determine whether
EGF (10 jzg/hr) could antagonize the antidiuretic effects of a
selective AVP V2-receptor agonist (l-desamino, D-Arg8 vaso-
pressin acetate, DDAVP) in conscious ewes and so cause
diuresis. The in vitro study was undertaken to investigate
further the effects of EGF on the binding of selective AVP V1
(vascular)- and V2-receptor antagonist ligands to their respec-
tive receptors, and on renal AVP V2-receptor-stimulated cAMP
production in rat renal inner medullary membranes.
Methods
In vivo studies
Experimental animals. Eight 2 to 2.5 year-old crossbred
(Border-Leicester x Merino) ewes (39 to 47 kg live weight) were
selected from a single flock. All ewes had been ovariectomized
under general anesthesia three months before the experiment in
order to exclude any influence of reproductive hormones on
fluid and electrolyte balance. General anesthesia was induced
using 800 mg sodium thiopentane (i.v. injection, Pentothal,
Boehnnger and Ingelheim, Melbourne, Australia) and main-
tained with a mixture of halothane (Fluothane, Id, Melbourne,
Australia) and oxygen. The crossover experiment was con-
ducted in four trials, separated by eight weeks to allow the
animals to recover from the previous experimental procedures.
Immediately before the first part of the experiment, the ewes
were shorn, weighed and randomly allocated to a group as-
signed to receive an i.v. infusion of isotonic saline alone
(control treatment) or recombinant hEGF (Auspep Pty. Ltd.,
Melbourne, Australia) in isotonic saline (EGF treatment). In the
second part of the crossover experiment, the infusions were
reversed such that all ewes received both types of infusion by
the end of the experiment (N = 8 per group). Animals were
housed with continuous light in a temperature-controlled (18 to
22°C) room.
Each ewe was kept in an individual metabolism cage that
allowed the separation and collection of urine and feces. Water
was available ad libitum and each ewe was offered 60:40
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lucerne: rolled barley (9.8 MJ metabolizable energy/kg, air dry).
The ration (0.6 to 0.8 kg) was offered in two halves at 1000 and
2115 hours daily. During the three weeks before each trial, the
ewes became accustomed to handling. All procedures on sheep
were carried out with the prior approval of the La Trobe
University Animal Experimentation Ethics Committee.
Experimental procedures. Two polyvinyl chloride catheters
(1.0 mm inner diameter by 1.5 mm outer diameter, Dural
Plastics, Sydney, New South Wales, Australia) were placed in
the jugular veins of each ewe four to five days before infusions
began, One catheter was used for infusion of saline or EGF, the
other for the collection of blood. In each trial, all ewes received
4 jig DDAVP (1 ml, Minirin, Ferring AB, Malmo, Sweden)
intramuscularly (i.m.) twice daily (at 0920 and 2100 hours) for
days 5 to 16. The ewes received a continuous i.v. infusion of 100
ml isotonic saline/day for eight days (days I to 8), followed by
0 (control treatment) or 10 jig EGF/hr (EGF treatment) in 100
ml isotonic saline for four days (days 9 to 12). Animals were
paired such that one control animal was examined whenever
one EGF-treated animal was studied. Subsequently all ewes
received 100 ml isotonic saline/day i.v. for four days (days 13 to
16). Infusates were kept in an ice-water bath and delivered
through a filter (0.22 jim, Millipore Corp., Bedford, Massachu-
setts, USA) using a peristaltic pump (Gilson, Minipuls 2, John
Morris Scientific Pty. Ltd., Balwyn, Victoria, Australia).
Blood samples (30 ml) were collected each day at 0900 hours
(before DDAVP administration) and water intake and urine
volume were measured [4] daily at 0930 hours. Feces were
collected and weighed every day and duplicate samples (—'90 g)
were dried overnight at 65°C for determination of the output of
fecal dry matter.
Blood measurements. Free-flowing blood was obtained for
measurement of microhematocrit (PCV), plasma sodium and
potassium concentrations (Instrumentation Laboratories, 501
ion specific electrode), osmolality (Wescor 5lOOC vapor pres-
sure osmometer) and hormone concentrations. Blood for
plasma AVP concentrations [11] was taken into chilled lithium
heparin tubes, and for plasma atrial natnuretic peptide (ANP)
concentrations [121 was taken into chilled sequesterene tubes
containing 500 kallikrein inhibitor units of aprotinin (Trasylol,
Bayer). All blood samples were placed on ice, centrifuged at
4°C and plasma stored at 4°C until assay for osmolality, sodium
or potassium or at —20°C for all other assays. Both radioimmu-
noassays had intra- and interassay coefficients of variation of
less than 8%. In a separate set of in vitro experiments it was
demonstrated that there was zero cross reactivity of the plasma
AVP assay to DDAVP (Minirin).
Urine measurements. Urine samples were centrifuged and
aliquots stored at 4°C until assayed for sodium and potassium
concentrations and for osmolality.
Statistical analysis. Since the effects of DDAVP were well-
known and the data of interest were those comparing EGF
treatment versus control on days 9 to 12 and the subsequent
period after this (days 13 to 16), data for these days were
analyzed by paired t-tests. Statistical significance was taken at
the P < 0.05 level. Data are presented as means SEM.
In vitro studies
Experimental animals. Female Sprague-Dawley rats (approx-
imately 250 g live weight) were obtained from the Biological
Research Laboratories, Austin Hospital. After sacrifice by
decapitation the kidneys were removed and renal inner medul-
lary membranes prepared according to the method of Trinder et
al [13]. All procedures on rats were carried out with the prior
approval of the Austin Hospital Animal Ethics Committee.
V2-receptor displacement assay. Renal inner medullary
membranes (250 jig) were incubated with binding buffer, the
AVP V2-receptor selective antagonist radioligand ([3H]-
desGlyNH29d(CH 2)5[D-Ile2Ile 4]AVP, 0.2 x 109M) as well as
AVP, DDAVP, a selective AVP V1-receptor antagonist (d(CH2)5
[Sar7]AVP, dSAVP), a selective AVP V2-receptor antagonist
(d(CH2)5[D-Ile2Ile4]AVP), oxytocin, angiotensin II (Auspep
Pty. Ltd.) or EGF at varying concentrations (l0— to l0' M).
The peptides were obtained from Peninsula Laboratories
(Parkville, Victoria, Australia), unless indicated otherwise. The
binding buffer consisted of 0.1 M Tris (pH 7.4), 0.01 M MgC12,
0.5 mg/mi bacitracin (Sigma, St. Louis, Missouri, USA), 100
lU/mi aprotinin (Sigma) and 0.1% bovine serum albumin (BSA,
CSL Ltd., Parkville, Victoria, Australia). The radioligand (Du-
pont, North Sydney, Australia) had a specific activity of 50.7
CiJmmol. Following a two hour incubation the samples were
filtered through Whatman GF/B glass fiber filters in a Brandel
filtration apparatus. The filters were rinsed three times with
wash buffer (0.1 M Tris pH 7.4, 0.01 M MgCI2 and 0.1% BSA).
Measurement of beta radiation was determined using a Packard
Tricarb 4530 for two minutes/sample with 60% efficiency.
Specific binding was measured as total binding minus nonspe-
cific binding determined by an excess of unlabeled AVP (10_6
M) and is shown as the percentage of bound/unbound in the
presence of AVP, related peptides, angiotensin II or EGF.
V1-receptor displacement assays. The AVP V1-receptor an-
tagonist radioligand [1251]-dSAVP was prepared by the chiora-
mine T method of iodination and HPLC purification [14] and
incubated (1 x,409 M) with renal inner medullary membranes
(250 jig), binding buffer (as above), and the same peptides as
above (10—s to 10- " M) for one hour at room temperature. The
bound and unbound ligands were separated as above and
gamma radiation measured (LKB Wallace 1260 Multigamma
counter) for one minute at an efficiency of 80%. Calculations
were as for the AVP V2-receptor binding assays.
cAMP determination. Adenylyl cyclase activity was mea-
sured using the method of Trinder et al [15]. Renal inner
medullary membranes were incubated in a medium containing
guanosine triphosphate (1 x l0- M, Sigma), iso-butyl-methyl-
xanthine (2 x i0 M, Sigma) in the presence or absence of
AVP. Stimulation of the reaction was initiated through the
addition of ATP (1 X 10 M, Sigma) and terminated after 10
minutes (37°C) through the addition of 0.15 M acetic acid. The
cAMP levels produced were measured by radioimmunoassay of
the supernatant (pH 7.4) after centrifugation using a commercial
kit (Amersham cyclic AMP [3H] Assay system TRK 432,
Buckinghamshire, UK). Sodium fluoride (NaF, 0.01 M), a
potent stimulator of G-proteins, was used as a positive control.
The levels of cAMP were measured as pmollmg protein per 10
minutes and expressed as a percent increase in cAMP from
basal levels. For an assay to be classified as successful, an a
priori requirement was for at least a 40% increase on basal
unstimulated cAMP production. To determine any inhibitory
effect of EGF on cAMP production, EGF (10k to 10' M) was
added to tubes containing AVP or NaF. Results are presented
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as the reduction in cAMP production after stimulation with
AVP or NaF.
Results
In vivo studies
At the end of the experiment, the mean live weight of the
ewes with the control treatment (N = 8) and EGF treatment(N = 8) was 42.4 1.4 kg and 42.4 1.3 kg, respectively.
Appetite response. All ewes ate most of the ration offered
throughout the experiment and the mean daily feed intake on
day 4 was 0.66 0.03 kg for the control ewes and 0.68 0.04
kg for ewes given the EGF treatment. There was no effect of
DDAVP injection nor EGF infusion on daily feed intake nor on
fecal dry matter output. The mean output of fecal dry matter on
day 4 was 0.16 0.02 kg and 0.16 0.02 kg for the ewes given
the control and EGF treatments, respectively.
Fluid balance. The mean daily urine volume (Fig. lA) was
relatively constant during days one to four (saline infusion
only), being 0.61 0.14 to 0.78 0.21 liters and 0.62 0.22 to
0.76 0.28 liters for the ewes given the control and EGF
treatments, respectively. After the twice-daily injections of
DDAVP commenced, mean daily urine volume during days five
to eight was reduced by 48% to 0.35 0.02 liter for the control
ewes and 0.36 0.01 liter for the EGF-treated ewes. The
control ewes which received DDAVP from day 5 onwards
maintained this pattern of reduced urine volume for the rest of
the experiment. By contrast, the simultaneous infusion of EGF
during DDAVP treatment induced an immediate and sustained
increase in urine volume (days 9 to 12, P < 0.05) of approxi-
mately 128% (to 0.82 0.05 liter) over DDAVP-induced
changes, approaching values recorded during the pretreatment
period (days 1 to 4). The urine volume of the EGF-treated ewes
fell slowly after the EGF infusions ceased and remained higher
than that of the control ewes on day 13 (P < 0.05) and day 16
(P < 0.01).
The daily water intake (Fig. 1 B) was also constant during the
pretreatment period (days 1 to 4), with mean values of 1.75
0.15 to 1.91 0.26 liters and 1.81 0.26 to 2.01 0.30 liters
being recorded for ewes in the control and EGF treatments,
respectively. As for urine volume, treatment with DDAVP
reduced water intake such that the mean daily water intake
during days five to eight was reduced by 25% (to 1.39 0.03
liter) for the control ewes and by 29% (to 1.37 0.04 liter) for
the EGF-treated ewes. The ewes given the control treatment
maintained this pattern of reduced water intake for the rest of
the experiment. By contrast, during the period of simultaneous
EGF infusion on days 9 to 12, water consumption increased
slowly towards pretreatment values. Water intake of the ewes
given EGF treatment was greater than that of the control ewes
on days 10 (P < 0.01) and 11 (P < 0.05) and the mean value of
the EGF-treated ewes for days 9 to 12 had increased to 1.79
0.10 liter (+ 30%). The daily water intake of the EGF-treated
ewes fell immediately after the EGF infusions ceased, reaching
levels recorded during the first period of DDAVP injections by
day 13.
Daily fluid balance (intake minus output in urine and feces)
was 0.94 0.12 to 1.12 0.15 liter and 0.98 0.16 to 1.22
0.12 liter for ewes given the control and EGF treatments,
respectively, throughout days one to four of the experiment
(Fig. 1C). There was no effect of DDAVP treatment on mean
fluid balance because of the spontaneous reduction in water
intake in parallel with DDA VP-induced antidiuresis. On the first
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Fig. 1. Daily (A) urine volume, (B) water intake and (C) fluid balance of
cross bred ewes before (days 1—4) and during (days 5—16) treatment(i.m. injections every 12 hr) with 4 ,sg DDAVP. Ewes also received a
continuous infusion (100 mLfday) of isotonic saline for 8 days (days 1—8),
then either 0 (O—O, N = 8) or 10 (D—D, N = 8) sg EGF/hour in
saline (100 mI/day) i.v. for 4 days (days 9—12), followed by saline (100
mi/day) for 4 days (days 13—16). Closed symbols refer to the period of
concomitant EGF infusion during DDAVP treatment. Plotted points
represent mean values and selected standard errors are shown as
vertical bars. *P < 0.05; a 0.01; *** a 0.001 for data during and
after EGF infusion versus control data on the same experimental day.
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Fig. 2. Daily (A) PCV, (B) plasma osmolality and plasma concentrations of(C) sodium and (D) potassium of crossbred ewes before (days 1—4)
and during (days 5—16) treatment (i.m. injections every 12 hr) with 4 pg DDA VP. Ewes also received a continuous infusion (100 mllday) of isotonic
saline for 8 days (days 1—8), then either 0 (O—O, N = 8) or 10 (D—D, N 8) pg EGF/hr in saline (100 mI/day) i.v. for 4 days (days 9—12),
followed by saline (100 mI/day) for 4 days (days 13—16). Closed symbols refer to the period of concomitant EGF infusion during DDAVP treatment.
Plotted points represent mean values and selected standard errors are shown as vertical bars. tP < 0.05; 0.01; *** 0.001 for data during
and alter EGF infusion versus control data on the same experimental day.
day of concurrent EGF treatment, the EGF-treated ewes went
into negative fluid balance by 0.20 liter (P < 0.05) compared
with the mean recorded during DDAYP treatment alone. This
indicates that the simultaneous infusion of EGF during DDAVP
treatment had an immediate diuretic effect. Thereafter, there
was no difference in fluid balance between the two treatments,
indicating that increases in water intake paralleled those of
urine volume for the rest of the experiment.
Hemazocrit. The PCV declined throughout the experiment,
irrespective of DDAVP or EGF dose (Fig. 2A), probably due to
blood sampling. There was a tendency for PCV to be greater
during EGF treatment (day 11, P = 0.07), perhaps due to
plasma volume contraction secondary to the diuresis and natri-
uresis (see below).
Plasma electrolyte and hormone responses. There was no
effect of DDAVP nor EGF treatment on plasma osmolality
again reflecting overall adjustment of water intake to changes in
urine volume (Fig. 2B). Plasma sodium concentration (Fig. 2C)
was transiently higher on the first day of EGF treatment (day 9,
P < 0.05) consistent with the effect on fluid balance (see above)
but did not differ at other times reflecting overall adjustment of
fluid balance. In addition, the plasma potassium concentration
was not affected by either treatment (Fig. 2D), but did increase
progressively throughout the experiment with both treatments.
There was no effect of DDAVP nor EGF on plasma AVP
(Fig. 3A) or ANP (Fig. 38), reflecting maintenance of fluid
balance.
Renal responses. The urinary excretion of sodium (Fig. 4A)
and potassium (Fig. 4B) was not affected by DDAVP treatment.
The profile of both parameters remained constant in ewes given
the control treatment throughout the experiment. However,
there was a significant effect of EGF infusion during DDAVP
treatment, such that urinary sodium excretion of the EGF-
treated ewes was transiently higher (day 9, P < 0.05; day 10,
P < 0.01) than that of the ewes given the control treatment.
During the latter part of the simultaneous treatment of EGF and
DDAVP (days 11 and 12), there was no difference in urinary
sodium excretion between the two treatments (Fig. 3A). Upon
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Fig. 3. Plasma concentrations of (A) AVP and (B) ANP of crossbred
ewes before (days 1—4) and during (days 5—16) treatment (i.m. injections
every 12 hr) with 4 pg DDAVP. Ewes also received a continuous
infusion (100 mI/day) of isotonic saline for 8 days (days 1—8), then either
0 (O—Q, N = 8) or 10 (D—D, N = 8) sg EGF/hour in saline (100
mllday) i.v. for 4 days (days 9—12), followed by saline (100 mI/day) for
4 days (days 13—16). Closed symbols refer to the period of concomitant
EGF infusion during DDAVP treatment. Plotted points represent mean
values and selected standard errors are shown as vertical bars. J1 <
0.05; 0.01; *** 0.001 for data during and after EUF infusion
versus control data on the same experimental day.
cessation of EGF infusion, the ewes previously infused with
EGF excreted less sodium alter a lag of one day (day 14, P <
0.02; day 15, P = 0.001) than did the ewes given the control
treatment. By day 16, there was no difference in urinary sodium
excretion between the two treatments. Similarly, during the
period of EGF treatment urinary excretion of potassium was
higher (day 9, P < 0.005; days 10 to 12, P <0.05) than that of
the control ewes. After cessation of EGF treatment, there was
no difference in urinary excretion of potassium between the two
treatments.
There was also an effect of DDAVP to increase urine osmo-
lality above values recorded during the pretreatment period
(Fig. 4C). Urine osmolality of the EGF-treated ewes throughout
EGF infusion was lower (P < 0.05) than that of the ewes given
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Fig. 4. Urinary excretion of (A) sodium, (B) potassium and (C) urine
osmolality of crossbred ewes before (days 1—4) and during (days 5—16)
treatment (i.m. injections every 12 hr) with 4 g DDAVP. Ewes also
received a continuous infusion (100 mI/day) of isotonic saline for 8 days
(days 1—8), then either 0 (O—O, N = 8) or 10 (D—D, N = 8) zg
EGF/hour in saline (100 mI/day) i,v. for 4 days (days 9—12), followed by
saline (100 mI/day) for 4 days (days 13—16). Closed symbols refer to the
period of concomitant EGF infusion during DDAVP treatment. Plotted
points represent mean values and selected standard errors are shown as
vertical bars. *P < 0.05; ** 0.01; *** 0.001 for data during and
after EGF infusion versus control data on the same experimental day.
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Fig. 5. Displacement of the spec/ic AVP Vreceptor antagonist radi-
oligand (13H1-desGlyNH29d(CH2)5[D-Ile2Ile IA VP) by the unlabeleled
peptidesAVP(D, 10 to 109M, N =3), DDA VP (I, 10_6 to 10"M,N = 2),dSA VP (A, io- to 10 M, N =2), d(CH2)5[D-11e211e4]AVP (U,1O_6 to 10" M, N = 2), oxytocin (, 10° to 10" M, N = 2),
angiotensin II (•, 10 to 10° M, N = 2) or EGF (0, i0 to i0 M,N = 3) using renal inner medullary membranes from female Sprague-
Dawley rats.
the control treatment, reflecting the concomitant diuresis in the
EGF-treated ewes at this time. After cessation of EGF treat-
ment, urine osmolality of the ewes previously treated with EGF
increased slowly towards that of the control ewes and values
remained lower only on day 13 (P < 0.05).
In vitro studies
V1- and V2-receptor displacement assays. AVP and its re-
lated peptides all displaced the specific binding of both [3H]-
desGlyNH29d(CH2)5[D-11e211e4]AVP and ['251]-dSAVP to the
renal inner medullary membranes in a dose-dependent manner
expected based on the prior classification of the analogues as
AVP V1- or V2-receptor selective (Figs. 5 and 6). However,
neither angiotensin II nor EGF displaced either radioligand,
demonstrating a lack of binding of EGF and angiotensin II to
either the renal AVP VI- or V2-receptor subtypes.
Adenylyl cyclase stimulation. EGF inhibited AVP-stimulated
cAMP production with IC50 2 x iO M but only inhibited
NaF-stimulated cAMP production at higher concentrations
(Fig. 7).
Discussion
The physiological role of EGF in the kidney is unclear. The
kidneys can synthesize prepro-EGF [161 and EGF [17] and
urine contains high EGF concentrations, some of which is
sequestered from plasma [8, 18—20]. Recently, receptors for
EGF have been reported in renal tubules from the dog [21],
rabbit [4, 5, 22], rat [23, 24] and sheep [20]. It is known that
EGF is mitogenic for renal tubular cells in vitro [1, 2] and in vivo
[3]. In addition, a direct renal tubular effect of EGF has been
Fig. 6. Displacement of the specific AVP V1-receptor antagonist radi-
oligand (['251J-dSAVP) by the unlabeleled peptides AVP (U, 10 to
10"M, N = 2), DDA VP (•, 1O to 10"M, N = 2), dSA VP (A, 10
to 10° M, N = 2), d(CH2)5fD-IIe2I1e4JAVP (U, iO to 10_Jo M, N =2),
oxytocin (, I0 to 10"M, N = 2), angiolensin II (•, 1O to 109M,
N = 2) or EGF (0, iO to 1O M, N =3) using renal inner medullary
membranes from female Sprague-Dawley rats.
suggested since microperfusion of isolated rabbit cortical col-
lecting tubules with EGF reduced the transport of sodium [5, 6]
and water [4].
Previous experiments have shown that i.v. infusions of low
doses of EGF into sheep resulted in dramatic increases in urine
volume and water intake [7—9] and that these EGF-induced
responses were dose-related. Natriuresis was also reported in
the studies, but was not dose-related, More recently, we [10]
demonstrated that the infusion of 10 g EGF/hr i.v. into water-
restricted sheep had direct renal diuretic effects. Since EGF
casued diuresis when water intake was restricted [10] the
EGF-induced polyuria and polydipsia demonstrated previously
[7—9] must have been due to a primary renal effect rather than a
primary effect to increase thirst and water intake with second-
ary polyuna. However, the molecular mechanism by which
EGF produced these renal effects was unclear. Possible mech-
anisms include antagonism of the AVP V2-receptor directly, its
second messenger system or its hydroosmotic effect.
The experiment reported here examined the first and second
of these proposals. The in vivo study showed that treatment of
sheep with the specific antidiuretic AVP V2-receptor antagonist
DDAVP halved urine volume, and concomitantly increased
urine osmolality and reduced water intake. Simultaneous treat-
ment of sheep with EGF dramatically reduced the DDAVP-
induced antidiuresis, with a return of water intake and urine
osmolality to pretreatment values. There was also an EGF-
induced transient natriuresis and kaliuresis. The diuretic effect
of EGF treatment was more immediate than its polydipsic
effect, and as a result there was an increase in water loss on the
first day of EGF infusion compared to that recorded during
0
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the 24 hour period of infusion [25, 26]. The differences in results
reported by us [9] and by these workers [25, 261 may indicate a
dose-response effect of EGF. However, if vasodilation and a
fall in blood pressure had occurred with EGF and/or DDAVP,
urine output would be expected to have fallen rather than
increase as seen here.
The mechanism(s) of the antagonistic action of EGF to
DDAVP was explored in the in vitro studies which demon-
strated no interaction between EGF and renal AVP VI- or
V2-receptors, but did show a dose-related inhibition of AVP-
stimulated cAMP production by EGF. This may explain the
previous finding of EGF inhibition of AVP-stimulated water
transport in rabbit cortical collecting tubules [4]; however, it
would not explain the inhibition of 8-chlorophenythio-cAMP-
stimulated water transport from the same study [4]. This
suggests that EGF may antagonize the antidiuretic action of
AVP at more than one site.
The effect of EGF on renal cAMP production has been
controversial. Teitelbaum [27] demonstrated that EGF inhibited
AVP-stimulated cAMP generation in epithelial cells from rat
inner medullary collecting tubules. However, others have sug-
gested a stimulatory effect of EGF on renal cAMP production
1 0 10_B 1 O- 1 10- 1 [22]. Our in vitro results confirm and extend those of Teitel-baum [27] in that we too demonstrated that EGF antagonized
AVP V2-receptor-stimulated cAMP production. Furthermore,
we reported no direct interaction of EGF with AVP-receptors.
Possible mechanisms for the effect of EGF on cAMP produc-
tion include EGF-stimulated phospholipase C activity or pros-
taglandin (PG) production. Phospholipase C antagonism, but
not phospholipase A antagonism or PG synthesis inhibition,
blocked the antagonistic effect of EGF against AVP-stimulated
cAMP production in vitro [27], suggesting a prominent role for
phospholipase C in this action of EGF.
However, it is known that EGF can stimulate PG synthesis
and the release of 3H-prostaglandins and 3H-arachidonic acid
from cultured canine kidney cells [28]. In isolated rat inner
medullary collecting duct cells [23] and rat renal glomerular
mesangial cells [29], EGF stimulated arachidonic acid release
and PGE2 synthesis, with resultant cAMP accumulation [23].
This EGF-stimulated PG synthesis was demonstrated to be
synergistic with the activation of protein kinase C [29]. The role
of PG on renal function includes direct renal effects and
antagonism of AVP at different cellular levels. In vivo treatment
of dogs with PG synthesis inhibitors enhanced the antidiuretic
effects of AVP, as indicated by increased urine osmolality and
decreased free water clearance, but there was no effect on
GFR, renal blood flow nor electrolyte excretion [30].
Thus EGF-induced synthesis of prostaglandins may be in-
volved in the effect of EGF to oppose the antidiuretic effects of
AVP. However, other studies have suggested that the pros-
taglandins may not be involved in the renal responses to EGF.
Prostaglandin synthesis inhibition did not influence the antago-
nistic action of EGF on AVP-stimulated water permeability [4],
EGF-induced thymidine incorporation [23] or EGF-induced
inhibition of adenylyl cyclase [27]. Thus controversy remains
concerning the interaction of EGF and the prostaglandins in
vivo.
The mechanism of the natriuretic effect of EGF is unclear.
AVP itself has been shown to be natriuretic. This may be via
tubular receptors in the medullary limb of the loop of Henle or
merely via plasma volume expansion [31]. EGF has been shown
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Fig. 7. Inhibition ofAVP- (0, N =3) andNaF- (•, N = 2) stimulated
cAMP production by EGF (1O— to io M) in renal inner medullary
membranes of female Sprague-Dawley rats.
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DDAVP treatment alone. However, the EGF-treated ewes
remained in stable fluid balance for the rest of the experiment.
Upon cessation of EGF infusion, the ewes responded with
lowered urine volume and water intake, as to be expected from
the concomitant DDAVP treatment. In addition, there was
reduced urinary excretion of sodium two to three days after the
cessation of EGF treatment, presumably to compensate for the
previous EGF-induced natriuresis. Despite these changes,
there was no effect of EGF treatment on plasma osmolality nor
plasma potassium, AVP or ANP concentrations, other than a
transient increase in plasma sodium concentration on the first
day of EGF treatment. This suggests that other sodium-retain-
ing hormonal systems (such as the renin-angiotensin-aldoste-
rone system) were operating to maintain the electrolyte profile.
Changes in glomerular filtration rate (GFR) cannot explain
the changes seen here, since we observed no difference in GFR
with EGF infused at similar or slightly higher doses in previous
experiments [9]. There was also no effect of chronic long-term
i.v. infusion of EGF (5 to 20 p.g/hr over 4 days) on mean arterial
blood pressure [9]. Previously, Scoggins et al [25] reported
higher cardiac output at one hour, higher heart rate, lower
stroke volume and total peripheral resistance at three hours,
followed by reduced mean arterial blood pressure at five hours
after the start of an i.v. infusion of a higher dose of EGF (125
pg/hr) into sheep. Carter et al [26] had similar observations as
well as vasodilation in the skin, thyroid and submaxillary glands
during the i.v. infusion of 129 g EGF/kg live weight over 24
hours into sheep. Both groups reported that heart rate remained
high and blood pressure had returned to normal by the end of
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to influence Na/H exchange in fibroblasts and cause depo-
larization of cortical collecting tubules [4]. However, this might
not produce natriuresis. In contrast, prostaglandins have been
shown to stimulate sodium and potassium excretion [32] in
addition to their effect to antagonize AVP. Therefore EGF-
stimulated PG production might also account for the natriuresis
and kaliuresis seen here possibly via a tubular action.
Whether or not these effects of EGF are physiological or
pharmacological remains to be clarified. Normally EGF is not
detectable in sheep plasma. Infusion of EGF at rates similar to
those used in this experiment produce plasma concentrations of
0.9 to 20.7 ,ag EGF/liter [7, 8]. Since EGF is produced locally in
the kidney [16, 17], local intrarenal concentrations may approx-
imate those that produce the diuretic effects seen here and in
other in vivo and in vitro studies. The dramatic responses of the
kidney in vivo to i.v. EGF infusion in this and in previous
studies [7—9] correspond to in vitro findings [4, 6] that EGF,
perfused extraluminally but not luminally, inhibited AVP-stim-
ulated water conductivity and sodium reabsorption from iso-
lated rabbit cortical collecting tubules. This suggests that local-
ly-formed or plasma-derived EGF might influence renal
electrolyte and water homeostasis possibly via regulation of the
AVP V2-receptor second messenger system by EGF-stimulated
phospholipase C activity and/or PG production.
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